Resources
44 Results (showing 21 - 30)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 6/6/2022 (updated 3/27/2024)
The Project Directors and Data Coordinator from Ohio’s Community of Practice Rural Community Opioid Response Program (CoP- RCORP) Consortium shared lessons from the field on collecting and managing data for the Biannual Progress Report. This presentation covered the approach and tools to collecting information for the Work Plan, Request for Information, and Excel Data Supplement. Supports for invoicing and effort reporting were also discussed.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.